The 2nd ISCC
October 15, 1997
Nagai Memorial Hall
Program
9:00-09:05
Haruo Sugano (Cancer Chemotherapy Center)
Welcome and Introduction
I. Future Directions for Drug Development by the NCI
Chairperson: Haruo Sugano (Cancer Chemotherapy Center)
9:05-9:35
Edward A. Sausville (NCI)
9:35-9:40
Discussion
9:40-9:55
Coffee Break
II-I. New Insights in Antimetabolites (Part I)
Chairpersons: Mace L. Rothenberg
(Univ. Texas)
Yutaka Ariyoshi (Aichi Hospital)
1. TS Inhibitors
09:55-10:20
Carmen J. Allegra (NCI)
Preclinical and clinical investigations of MTA
10:20-10:45
Mark P. Smith (Zeneca Pharmaceuticals, UK)
Raltitrexed (TomudexTM) combinations: Phase I trials
10:45-11:00
Keisuke Aiba (Cancer Chemotherapy Center)
Clinical trials with raltitrexed in Japan
11:00-11:15
Discussion
2. Gemcitabine
11:15-11:30
Masahiro Fukuoka (Kinki Univ.)
Gemcitabine in non-small cell lung cancer
11:30-11:55
Mace L. Rothenberg (Univ. Texas)
Current status of gemcitabine in the United States
11:55-12:10
Discussion
12:10-13:10
Lunch Break
II-II. New Insights in Antimetabolites (Part II)
Chairpersons: Edward A. Sausville
(NCI)
Noboru Horikoshi (Cancer Chemotherapy Center)
3. Modified Cytosine Nucleosides Developed in Japan
Akira Matsuda (Hokkaido Univ.)
Chemical overview of modified cytosine nucleosides
13:25-13:35
Masanori Miwa (Nippon Roche Research Center)
Positive correlation between antitumor activity of 2'-deoxy-2'-methylidenecytidine (DMDC) and cytidine deaminase activity in tumors and its possible mechanism
13:35-13:45
Junji Kanazawa (Kyowa Hakko Kogyo Co.)
Mechanism of antitumor activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine (FMDC), a new 2'-deoxycytidine antimetabolite
13:45-13:55
Tomowo Kobayashi (Sankyo Co.)
Antitumor activity of a novel nucleoside l-(2-C-cyano-2-deoxy-b-D-arabino-pentofuranosyl)-N4-palmitoylcytosine (CS-682)
13:55-14:05
Yuji Shimamoto (Taiho Pharmaceutical Co.)
Novel antitumor ribonucleoside, 3'-ethynylcytidine: antitumor activity and pharmacology
14:05-14:20
Discussion
14:20-14:35
Coffee Break
III. New Antitumor Agents : Basic and Clinical Aspects
Chairpersons: Bruce
A. Chabner (MGH Cancer Center)
Takashi Tsuruo (Univ. Tokyo)
1.Cryptophan
14:35-15:00
Frederick A. Valeriote (Wayne State Univ.)
2. Flavopiridol
15:00-15:25
Edward A. Sausville (NCI)
Preclinical and clinical studies with flavopiridol
3. Thrombopoietin
15:25-15:50
David J. Kuter (MGH Cancer Center)
Thrombopoietin : biology and applications in oncology
4. TOP-53
15:50-16:05
Takashi Kobunai (Taiho Pharmaceutical Co.)
Preclinical-pharmacology and early clinical development of TOP-53, a novel podophyllotoxin derivative
5. CGP57148
16:05-16:20
Shingo Dan (Univ. Tokyo)
Selective induction of apoptosis in Philadelphia chromosome-positive K562 cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148
6. E7070
16:20-16:35
Kentaro Yoshimatsu (Eisai Co.)
E7070: a novel sulfonamide antitumor agent, targeting Gl phase
16:35-16:55
Coffee Break
IV. Development of New Antitumor Agents in Europe and Japan: Present Situation and Future Perspectives
Chairpersons: Yasuhiro Shimada (National Cancer Center
Hospital)
Yasutsuna Sasaki (National Cancer Center Hospital East)
16:55-17:15
Coenraad van Kalken (EORTC-New Drug Development Office, Netherlands)
New anticancer drug development in Europe; the approach of the European Organization for Research and Treatment of Cancer (EORTC)
17:15-17:35
Nagahiro Saijo (National Cancer Center Research Inst.)
Development of new antitumor agents in Europe and Japan: present situation and future perspectives
17:35-17:50
Discussion
V. Chemotherapy and the Elderly: What We Know and What We Think We Know
Chairperson: Makoto Ogawa (Aichi Cancer Center)
17:50-18:20
Bruce A. Chabner (MGH Cancer Center)
18:20-18:25
Discussion
Closing Remark
18:25-18:30
Takashi Tsuruo (Univ. Tokyo)
18:30-19:30
Mixer
